Kymera launches parallel Phase 2b trials for STAT6 degrader KT-621 in atopic dermatitis and eosinophilic asthma, with readouts staggered...

Cartesian Therapeutics R&D spending doubles to $19.5M in Q1 2026 as cash runway tightens to mid-2027, with Phase 3...

Rezolute's ersodetug misses primary endpoint in congenital hyperinsulinism trial, though secondary CGM data shows consistent hypoglycemia reductions across anal

FDA approves vepdegestrant for ESR1-mutant breast cancer, the first PROTAC protein degrader cleared. Median PFS improved to 5.0 months...

Protocol complexity now drives 76% of trials to at least one amendment—here's what that costs sites in activation days,...

Apotex receives Health Canada approval for generic semaglutide injection, matching all commercial formats of Novo Nordisk's Ozempic for type...

BioMarin's vosoritide demonstrates sustained height gains in achondroplasia over eight years, with stable proportions and preserved bone mineral density.

Cartesian Therapeutics reports Q1 2026 results with $120.4M cash and mid-2027 runway amid three simultaneous CAR-T trials.

Kymera advances STAT6 Degrader KT-621 in Phase 2b trials for atopic dermatitis and asthma, testing oral transcription factor degradation...

Rezolute's ersodetug missed its primary endpoint but demonstrated consistent CGM-based improvements in time in hypoglycemia across multiple analyses.